Good Doctor·Hyperthermic Perfusion | Literature Review and Analysis | (7) “Clinical Study on Cytoreductive Surgery Combined with Intraperitoneal Hyperthermic Perfusion Chemotherapy for Peritoneal Metastases of Gastric Cancer”
This study evaluated the therapeutic efficacy and adverse effects of hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal metastases from gastric cancer, following cytoreductive surgery (CRS).
2026-08-21

[Abstract]
This study evaluated the therapeutic efficacy and adverse effects of hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal metastases from gastric cancer, following cytoreductive surgery (CRS). The results showed that among patients who underwent CRS alone, the mortality rate during the follow-up period (median 30 months, range 3.0–85.5 months) was 93.3% (42/45), whereas in the CRS plus HIPEC group it was 77.0% (47/61; P < 0.05). The median survival in the CRS group (7.0 months, 95% CI: 5.8–8.2 months) was significantly shorter than that in the CRS plus HIPEC group (11.1 months, 95% CI: 8.3–13.9 months; P = 0.003). There was no significant difference between the two groups in the incidence of treatment‑related severe adverse events (P > 0.05). Multivariate analysis identified HIPEC, “concurrent peritoneal carcinomatosis” (i.e., pre‑CRS peritoneal metastases), macroscopically complete cytoreduction, the occurrence of severe adverse events, and six cycles of systemic chemotherapy as independent prognostic factors.
丨Article丨Source丨Core丨Background丨
“Clinical Study on Cytoreductive Surgery Combined with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Metastases from Gastric Cancer” — Chinese Journal of Clinical Oncology, Volume 39, Issue 22 (Li Yan, Zhou Yunfeng, Xie Conghua, Peng Chunwei, Huang Chaoqun, Yang Xiaojun, Cheng Fulin, Xiong Bin, Yang Guoliang)
Objective: To evaluate the efficacy and safety of cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of peritoneal carcinomatosis from gastric cancer (gcPC).
[Keywords] Gastric cancer peritoneal metastasis (gcPC), cytoreductive surgery (CRS), hyperthermic intraperitoneal chemotherapy (HIPEC)







Academic Commentary and Analysis
Characteristics/Advantages of This Study
The scientific rigor and forward-looking nature of the study design
Peritoneal metastasis following radical gastrectomy remains a longstanding clinical challenge; in approximately half of patients, recurrence initially manifests as peritoneal implantation. Conventional intravenous chemotherapy alone offers only limited efficacy in eradicating peritoneal metastases. The authors’ institution began developing an integrated strategy for the prevention and treatment of peritoneal metastases as early as 2003. At that time, in Europe, North America, Japan, and China, cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) were still in their nascent stages of application to peritoneal malignancies, with no established expert consensus or standardized clinical guidelines available domestically or internationally. Against this backdrop, this study initiated a prospective, randomized controlled trial in 2007, enrolling 68 gastric cancer patients by 2010 and subsequently adding another 38, for a total of 106 patients with gastric cancer–related peritoneal carcinomatosis (gcPC) at the time of publication in 2012. All patients underwent cytoreductive surgery (CRS), with 45 assigned to the CRS-alone group and 61 to the CRS plus HIPEC combination group.
In-depth analysis of research findings
In addition to comparing median overall survival (Figure 1), this study retrospectively analyzed mortality rates during the follow-up period in both groups. The results demonstrated that CRS plus HIPEC significantly prolongs overall survival and reduces mortality in patients with peritoneal metastases from gastric cancer.
This study focuses on analyzing the impact of HIPEC on the survival outcomes of patients with “synchronous peritoneal metastases” and those with “metachronous peritoneal metastases.” In this context, “synchronous peritoneal metastases” are defined as peritoneal metastases present at the time of initial diagnosis of gastric cancer, whereas “metachronous peritoneal metastases” refer to peritoneal metastases detected during follow-up after curative resection for gastric cancer. Based on an analysis of the three clinical application paradigms of HIPEC outlined in the CACA guidelines, the former corresponds to a “therapeutic” approach, while the latter represents a “preventive” strategy. Our findings indicate that HIPEC exerts a significant therapeutic effect in the former scenario, with a median overall survival (OS) of 7.0 months in the CRS group versus 16.0 months in the CRS plus HIPEC group (P = 0.002; Figure 2A). By contrast, no significant difference was observed in the latter scenario (Figure 2B). Given the limited sample size of this study, the preventive efficacy of HIPEC against peritoneal metastases following curative gastrectomy, as well as its clinical implications, remain to be confirmed by large‑scale, randomized controlled trials.
The impact of the extent of CRS on overall survival, as shown in Figure 3, was expected and consistent with findings reported by other investigators: patients achieving complete cytoreduction (CC0, no macroscopically visible residual disease) or near‑complete cytoreduction (CC1, residual lesions ≤2.5 mm) had a significantly longer median OS (11.5 months) compared with those who did not achieve complete or near‑complete cytoreduction (CC2, residual lesions 2.5–5.0 mm; CC3, residual lesions ≥5.0 mm), whose median OS was 4.8 months. More importantly, regardless of whether the CRS achieved complete tumor debulking—i.e., irrespective of the CC score—this study demonstrated that postoperative HIPEC significantly prolonged overall survival (11.5 vs. 14.3 months; 4.8 vs. 8.2 months; P = 0.002).
The incidence of serious adverse events (SAEs) with HIPEC (Figure 4), as well as the impact of combining systemic chemotherapy with HIPEC on the survival outcomes of patients with gastric cancer and peritoneal carcinomatosis (Figure 5), were also consistent with expectations. No further elaboration is necessary.
Analysis of overall survival during the follow-up period in this study demonstrated that HIPEC significantly improved 1-year survival (20.0% in the CRS group vs. 39.3% in the CRS+HIPEC group, P<0.05). However, no significant effect was observed on 2-year or 3-year survival rates, suggesting that HIPEC effectively and locally eradicates free cancer cells and microscopic residual tumor foci within the peritoneal cavity, thereby markedly reducing local recurrence within the first year after surgery—indicating a pronounced short-term benefit but limited long-term efficacy. Therefore, to enhance the long-term outcomes of therapeutic HIPEC, we recommend administering multiple cycles of HIPEC postoperatively, with each cycle consisting of three sessions spaced 1–2 days apart and lasting 3–4 weeks.
A Comparison of HIPEC Technology: Then and Now
Differences in perfusate volume and drug concentration: In this study, a 12‑L large‑volume saline solution was used as the perfusate, combined with a regimen of hydroxycamptothecin plus mitomycin or cisplatin plus docetaxel, and a 90‑minute perfusion was performed using a 6‑L open‑circuit system. The exceptionally large dilution volume of 12 L markedly reduces the effective intraperitoneal drug concentration; meanwhile, such a high‑volume perfusion can exacerbate compression of intraabdominal organs, increasing the risks of circulatory instability and electrolyte disturbances. Modern standardized protocols typically employ a closed‑loop perfusate volume of 3,000 ± 500 mL, which, at the same total chemotherapy dose, results in a significantly higher drug concentration. Under constant‑temperature conditions of 42–43°C, hyperthermic chemotherapy exhibits a more potent synergistic cytotoxic effect, balancing therapeutic efficacy with patient tolerability.
Temperature Control and Circulation Mode: The original device employed an open, non‑circulating system, requiring 30 minutes to reach the target temperature with a control accuracy of ±0.5°C. In contrast, today’s mainstream devices utilize an instant‑heat closed-loop circulation system, significantly reducing the time needed to achieve the therapeutic temperature while delivering temperature control accuracy of ±0.1°C. Throughout the entire treatment, the temperature remains stable without any decline, consistently maintaining the optimal therapeutic window of 42–43°C, thereby preventing insufficient efficacy due to sub‑optimal temperatures and avoiding overheating‑induced damage to healthy tissues.
Tube‑occlusion prevention and drug‑administration protocols: At the time, domestic HIPEC equipment was still under development. The thermal perfusion system used in this study lacked both continuous circulation and fluid‑exchange capabilities, as well as any filtration design. Today, certain Chinese manufacturers offer HIPEC devices that not only incorporate fluid‑exchange functions and dual‑stage filtration to prevent tube blockages and ensure effective circulation throughout the procedure, but also maintain constant temperature and pressure during treatment. Furthermore, while the original article did not specify a standardized dosing protocol, current practice follows the CACA guidelines, employing body surface area–based precise dosing to achieve standardized therapy.
Comprehensive Evaluation and Overall Academic Contribution
This was a clinical controlled study conducted in the early stages, when HIPEC technology had not yet been standardized, and it was distinctly exploratory and pioneering. The study’s clinical data demonstrated that HIPEC can significantly prolong overall survival in patients with peritoneal metastases from gastric cancer, reducing mortality without substantially increasing the incidence of severe adverse events. Its core value lies not only in providing a viable therapeutic pathway for clinical practice at the time, but also in accumulating valuable evidence‑based medical evidence to support the subsequent standardized development of HIPEC in China.
Expert Profile

Dr. Liu, M.D., Ph.D.
Professional Society Member
American Society for Cell Biology (2006–present)
American Heart Association (2006–present)
American Thoracic Society (1997–present)
2023–2025.5 Associate Professor, Department of Cardiology, University of Miami, USA
1999–2023 Assistant/Associate Professor, Division of Pulmonary and Critical Care Medicine, University of Nebraska Medical Center, USA
1996–1999 Postdoctoral Fellow, Department of Pulmonary and Critical Care Medicine, University of Nebraska Medical Center, USA
1992–1995: Master of Medicine, Department of Respiratory Medicine, Xijing Hospital, Fourth Military Medical University (under Professor Sun Bin)
1986–1992: Clinical Physician, Department of Respiratory Medicine, General Hospital of the Shenyang Military Region
1981–1986 Bachelor of Medicine, Department of Clinical Medicine, Fourth Military Medical University
Key words:
Related News